Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Juan Moreno‐Rubio et al.|Molecular Cancer Therapeutics|2014Cited by 12
Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PI3KCA</i> wild type (4WT). GEMCAD 1601 PIER trial.Carlos Fernández-Martos, Carles Pericay, Joan Maurel et al.|Journal of Clinical Oncology|2021Cited by 3
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Encarna Andrada et al.|Unknown|2023Cited by 0
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Juan Moreno‐Rubio et al.|Unknown|2023Cited by 0
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Juan Moreno‐Rubio et al.|Unknown|2023Cited by 0